Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Mantel cell lymphoma~* CD 20+~* At diagnosis or without anterior chemotherapy~* Age \>18 and \< 66 years~* Ann Arbor ii, III or IV~* ECOG \<3~* contraindication for rituximab treatment~* Informed consent signed~* No cancer anteriory~* Renal and hepatic function compatible with the treatment~* Ventricular Fraction \> 50 % with echographic method and \> 40% with isotopic method~Exclusion Criteria:~* Other type of lymphoma~* age\<18 ou \> 66 years~* Informed consent not signed~* anterior cancer~* Contraindication to rituximab~* Cardiac insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VAD Clorambucil Rituximab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).